VCTE vs. histology in MASLD
The study included 3,532 adults with MASLD.
-
By
-
Doug Brunk
-
January 6, 2026
-
Clinical Scorecard: VCTE vs. Histology in MASLD
At a Glance
| Category | Detail |
|---|
| Condition | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
| Key Mechanisms | Vibration-controlled transient elastography (VCTE) for liver stiffness measurement (LSM) |
| Target Population | Adults with MASLD |
| Care Setting | Multi-center clinical settings |
Key Highlights
- VCTE-derived LSM predicts liver-related events (LREs) comparably to liver biopsy.
- Study involved 3,532 adults with a median follow-up of 56.6 months.
- 3.6% of patients developed LREs, primarily due to hepatic decompensation.
- Five-year AUROC values for LSM and histology were nearly identical (0.870 vs 0.869).
- LSM may serve as a practical alternative to histology in clinical trials.
Guideline-Based Recommendations
Diagnosis
- Use VCTE for assessing liver stiffness in MASLD patients.
Management
- Consider LSM as a surrogate prognostic endpoint in clinical trials.
Monitoring & Follow-up
- Regularly assess liver stiffness to stratify risk in MASLD patients.
Risks
- Monitor for hepatic decompensation and liver-related events.
Patient & Prescribing Data
Adults with MASLD, average age 51.9 years, 57.3% male.
One-third of patients had advanced fibrosis (F3–F4) on histology.
Clinical Best Practices
- Utilize VCTE for non-invasive monitoring of liver stiffness.
- Integrate LSM findings with clinical assessments for comprehensive care.
References
